What is the role for Glycoprotein IIb/IIIa inhibitor use in the catheterisation laboratory in the current era?
CONCLUSION: Because of the persistent benefit of GPI in limiting early ischemic complications, especially in higher risk clinical and/or anatomical subsets, and the associated risk of increased bleeding complications, also in contemporary PCI, these agents should currently be used on a selective rather than routine basis, including bail out administration for peri-procedural thrombotic complications.
PMID: 29345590 [PubMed - as supplied by publisher]
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Rubboli A, Patti G Tags: Curr Vasc Pharmacol Source Type: research
More News: Abciximab | Angiomax | Angioplasty | Aspirin | Bleeding | Blood Transusion | Clopidogrel | Coronary Angioplasty | Drugs & Pharmacology | Eptifibatide | Heart Attack | Integrilin | Laboratory Medicine | Percutaneous Coronary Intervention | Plavix